Penumbra Receives FDA Clearance for Lightning CAVT Technology to Treat DVT

Key Facts

1Penumbra received FDA clearance for its Lightning computer-assisted vacuum thrombectomy (CAVT) technology to treat deep vein thrombosis (DVT).

Penumbra received FDA clearance for its Lightning computer-assisted vacuum thrombectomy (CAVT) technology to treat deep vein thrombosis (DVT). PR Newswire reported that the clearance is supported by safety and efficacy data from the BOLT-DVT clinical trial, expanding the clinical application of the company's technology to a broader patient population.

PEN closed at $322.41 on October 19, 2026, prior to the announcement of the expanded indication for its thrombectomy devices. The regulatory milestone follows a session where the stock reached a high of $322.87 and a low of $320.3 on October 19, 2026.